Abstract 5658
Background
A convenient and accurate method to improve the effectiveness of colorectal-cancer screening is still under exploration. This may be achieved by a diagnostic model based on 5-hydroxymethylcytosine (5-hmC).
Methods
We collected peripheral venous blood from 285 colorectal cancer patients and 285 healthy people at Zhongshan Hospital, Shanghai. The 5-hmC level of each gene locus in circulating-free DNA (cfDNA) was detected using a highly sensitive sequencing method. Of 285 subjects, 178 in each group were randomly selected as training set. The first 100 gene loci with the most significant difference of 5-hmC level were selected for establishing a diagnostic model (Logistic regression model) based on machine-learning method. The rest subjects in each group were used as validating set to validate this model. Further, we analysed the influence of several clinicopathological factors on 5-hmC level.
Results
In training set, the comprison of the 5-hmC level suggested that the expression of 5-hmC in cfDNA was significantly different between the two groups. Of the 100 gene loci, 35 were included in the model. In internal validation, the sensitivity and specificity of the model were 88.8% and 89.9%, respectively. While the sensitivity and specificity 81.3% and 89.7%, respectively, in external validation using the validating set. The area under ROC curve of external validation was 0.946. For colorectal cancer stages I-IV, the diagnostic sensitivities were 78.7%, 81.9%, 88.2% and 95.6%, respectively. We also found that age, gender, Ras status or the site of primary tumor had no significant effect on the expression of 5-hmC. However, there was a statistically difference of 5-hmC level between stage I-III and stage IV.
Conclusions
Our study identified the gene loci with significantly different 5-hmC level between colorectal cancer patients and healthy people, then we established a diagnostic model of colorectal cancer with high sensitivity and specificity. However, the utility of the model still need further verification in large-scale screening experiments.
Clinical trial identification
NCT03599947 09/16/2018.
Editorial acknowledgement
Shanghai Yibien Gene Technology Co., Ltd. Provides Testing Platform.
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3516 - Palbociclib Rechallenge in Hormone Receptor (HR)[+]/HER2[-] Advanced Breast Cancer (ABC). PALMIRA Trial
Presenter: Antonio Llombart Cussac
Session: Poster Display session 2
Resources:
Abstract
4616 - Alpelisib (ALP) + Endocrine Therapy (ET) by Last Prior Therapy in Patients (pts) With PIK3CA-Mutated Hormone-Receptor Positive (HR+) Human Epidermal Growth Factor Receptor-2-Negative (HER2–) Advanced Breast Cancer (ABC): Additional Study Cohort in BYLieve
Presenter: Eva Ciruelos
Session: Poster Display session 2
Resources:
Abstract
3592 - PRECYCLE: Impact of CANKADO-based eHealth-support on quality of life in metastatic breast cancer patients treated with palbociclib and endocrine therapy.
Presenter: Tom Degenhardt
Session: Poster Display session 2
Resources:
Abstract
4168 - Efficacy and safety of oral poly (ADP-ribose) polymerase inhibitor fluzoparib in patients with BRCA1/2 mutations and platinum sensitive recurrent ovarian cancer
Presenter: Ning Li
Session: Poster Display session 2
Resources:
Abstract
2785 - Effect of response to last platinum-based chemotherapy in patients (pts) with platinum-sensitive, recurrent ovarian carcinoma in the phase 3 study ARIEL3 of rucaparib maintenance treatment
Presenter: Jonathan Ledermann
Session: Poster Display session 2
Resources:
Abstract
3496 - Integrated safety analysis of the poly(ADP-ribose) polymerase (PARP) inhibitor rucaparib in patients (pts) with ovarian cancer in the treatment and maintenance settings
Presenter: Rebecca Kristeleit
Session: Poster Display session 2
Resources:
Abstract
2844 - Clinical factors associated with prolonged response and survival under olaparib as maintenance therapy in BRCA mutated ovarian cancers
Presenter: S.Intidhar Labidi-Galy
Session: Poster Display session 2
Resources:
Abstract
1955 - A Prospective Evaluation of Tolerability of Niraparib Dosing Based on Baseline Body Weight (BW) and Platelet (plt) Count: Blinded Pooled Interim Safety Data from the NORA Study
Presenter: Xiaohua Wu
Session: Poster Display session 2
Resources:
Abstract
2539 - Evaluation of Niraparib 200 mg/d as Maintenance Therapy in Recurrent Ovarian Cancer and Associated Thrombocytopenia in a Real-World US Setting
Presenter: Premal Thaker
Session: Poster Display session 2
Resources:
Abstract
1290 - Niraparib initial dose and its’ management in patients with recurrent high-grade serous ovarian cancer.
Presenter: Jacek Grabowski
Session: Poster Display session 2
Resources:
Abstract